Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Sustained delivery of a HIF-1 antagonist for ocular neovascularization — Takeshi Iwase (2013) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Sustained delivery of a HIF-1 antagonist for ocular neovascularization
Shared by
Gregg L. Friedman
Johns Hopkins University
Sustained delivery of a HIF-1 antagonist for ocular neovascularization
Article
2013
en
Authors
+15 more
TI
Takeshi Iwase
JF
Jie Fu
TY
Tsunehiko Yoshida
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2016
The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization
Mingbing Zeng
,
Jikui Shen
,
Yuanyuan Liu
,
Lucy Yang Lu
,
Kun Ding
,
Seth D. Fortmann
,
Mahmood Khan
,
Jiangxia Wang
,
Sean F. Hackett
,
Gregg L. Friedman
,
Peter A. Campochiaro
Article
2010
Digoxin inhibits retinal ischemia‐induced HIF‐1α expression and ocular neovascularization
Tsunehiko Yoshida
,
Huafeng Zhang
,
Takeshi Iwase
,
Jikui Shen
,
Gregg L. Friedman
,
Peter A. Campochiaro
Article
2015
Silk hydrogels for sustained ocular delivery of anti-vascular endothelial growth factor (anti-VEGF) therapeutics
Michael L. Lovett
,
Xiaoqin Wang
,
Tuna Yücel
,
Lyndsey York
,
Marc Keirstead
,
Linda Haggerty
,
David Kaplan
Article
2014
Silk-based biomaterials for sustained drug delivery
Tuna Yücel
,
Michael L. Lovett
,
David Kaplan
Article
2021
Silk Reservoir Implants for Sustained Drug Delivery
Alexander J. Wolfe
,
Jeffrey Guasto
,
Fiorenzo G. Omenetto
,
David Kaplan
Discussion(0)
No comments yet. Be the first to comment.